DNA Health Test

EliteMedical offers DNA health testing that analyses 47 genes organised across eight preventive health categories: oxidative stress and antioxidant capacity, detoxification ability, inflammation predisposition, methylation and gene expression regulation, lipid and cholesterol metabolism, bone health, insulin sensitivity, and vitamin metabolism (vitamins A, D, C, and B12). The test is performed from a simple saliva or blood sample and results are interpreted in Czech by an EliteMedical physician or health specialist, with personalised recommendations covering diet, supplementation, and lifestyle adjustments based on the patient's specific genetic variants. Unlike diagnostic genetic tests for monogenic diseases, this test focuses on polygenic health trait variants — the kind that influence susceptibility and response to lifestyle interventions. It is particularly valuable for people with a strong family history of chronic disease (cardiovascular, metabolic, bone, or inflammatory conditions) who want to understand their personal risk landscape before symptoms emerge.

Genetic health testing at EliteMedical uses a multi-gene panel approach to assess clinically actionable variants in 47 genes associated with eight foundational aspects of metabolic and preventive health. This is not a diagnostic genetic test for monogenic conditions (like BRCA testing) — it is a polygenic lifestyle optimisation tool that identifies variants where nutrition, supplementation, and behaviour can meaningfully modify risk or improve outcomes. **The 8 tested categories and their clinical relevance:** 1. **Oxidative stress and antioxidant capacity** — variants in SOD2 (superoxide dismutase), GPX1 (glutathione peroxidase), CAT (catalase), and NQO1 affect the efficiency of the body's antioxidant defence system. Patients with reduced antioxidant gene variants may benefit from targeted antioxidant supplementation (CoQ10, NAC, vitamin E) and reduced exposure to oxidative stressors (alcohol, cigarette smoke, environmental toxins). 2. **Detoxification ability (Phase I and II liver enzymes)** — variants in CYP1A1, CYP1B1, CYP2C9, CYP3A4 (Phase I) and GSTM1, GSTT1, GSTP1, NAT2 (Phase II) affect how efficiently the liver processes drugs, hormones, and environmental toxicants. Slow metabolisers may respond differently to certain medications and should discuss this with prescribing physicians. 3. **Inflammation predisposition** — variants in IL-6, IL-1B, TNF-alpha, CRP promoter regions affect baseline inflammatory tone. Patients with pro-inflammatory genotypes may benefit from anti-inflammatory dietary patterns (Mediterranean diet, omega-3 supplementation) and regular inflammatory marker monitoring. 4. **Methylation and gene expression regulation (MTHFR and related genes)** — variants in MTHFR (C677T, A1298C), MTRR, CBS, and COMT affect folate metabolism, homocysteine clearance, and DNA methylation. MTHFR variants are clinically relevant for folate dosing in pregnancy, homocysteine-related cardiovascular risk, and neurotransmitter balance. 5. **Lipid and cholesterol metabolism** — variants in APOE (the most studied: APOE ε4 confers elevated LDL and increased Alzheimer's risk), PCSK9, LPL, APOA5, and LDLR affect lipid processing and cardiovascular risk. APOE genotyping in particular has direct implications for dietary fat choices and cardiovascular screening intensity. 6. **Bone health** — variants in VDR (vitamin D receptor), COL1A1 (collagen type I), and BMP2 affect bone mineral density and fracture risk. VDR variants may indicate a need for higher vitamin D supplementation to achieve the same receptor activation as a typical patient. 7. **Insulin sensitivity** — variants in PPARG, ADIPOQ, TCF7L2, and IRS1 affect insulin signalling and glucose metabolism efficiency. Patients with insulin-resistance genotypes benefit from low-glycaemic dietary approaches and resistance exercise programmes. 8. **Vitamin metabolism (A, D, C, B12)** — variants in BCMO1 (beta-carotene to vitamin A conversion), GC (vitamin D-binding protein), SLC23A1/2 (vitamin C transport), and TCN2 (transcobalamin II, B12 transport) affect whether standard dietary intake achieves adequate cellular vitamin levels. **The process:** A saliva sample or blood draw is taken at EliteMedical. The sample is sent to the accredited laboratory. Results are produced in a comprehensive Czech-language report within approximately 2–4 weeks. A consultation with the health specialist (František Knobloch) or the coordinating physician reviews the report and produces personalised recommendations covering dietary adjustments, targeted supplementation protocol, and lifestyle priorities based on the specific variant profile. **Who benefits most:** People with family history of heart disease, cancer, osteoporosis, or metabolic disease; patients interested in precision nutrition or biohacking; those seeking to understand differential medication responses; anyone who has received a blood test flag (high LDL, elevated homocysteine) without a clear lifestyle explanation. **Limitations:** This test assesses variant prevalence, not diagnostic certainty — having a risk variant does not mean disease is inevitable, and absence of a risk variant does not guarantee protection. Results should be interpreted in clinical context, which the EliteMedical consultation ensures.